Mansour Esmailidehaj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mansour Esmailidehaj has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Bahram Rasoulian
Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
7 shared publications Ali Khoshbaten
Research Center for Trauma, Baqiyatallah University of Medical Sciences, Tehran, Iran
6 shared publications- Mohammad Rezvani
Department of Physiology, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
5 shared publications - Babak Baharvand
Madani Heart Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran
3 shared publications Hannaneh Wahhabaghai
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications- Mohsen Foadoddini
Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
3 shared publications
Latest Publications
- 3 May 2026
- Published by Maad Rayan Publishing Company in Journal of Kerman University of Medical Sciences
- Vol. 33  (1) , 1-9
MG53 as a Potential Therapeutic Target for Myocardial Infarction Injury
Introduction: Myocardial infarction (MI) leads to irreversible cardiomyocyte loss and progressive ventricular remodeling largely driven by oxidative stress, inflammation, and mitochondrial dysfunction. Mitsugumin 53 (MG53/TRIM72) is a muscle-enriched membrane-repair protein that has emerged as a multifunctional regulator of cellular antioxidant responses, mitochondrial integrity, and anti-inflammatory signaling. This review synthesizes current evidence on the MG53’s mechanisms and therapeutic potential in MI. Methods: We performed a narrative review of preclinical and translational literature focusing on MG53 in cardiac injury. Databases searched included PubMed and Google Scholar (through 2025), using keywords "MG53," "TRIM72," "myocardial infarction," "isch-emia-reperfusion," "recombinant MG53," and "cardioprotection." Relevant mechanistic studies, recombinant protein interventions, and reports on the MG53’s systemic effects and safety were prioritized. Results: Preclinical studies demonstrate that MG53 promotes plasma-membrane resealing, preserves mitochondrial membrane potential, reduces mitochondrial ROS production, attenuates mitophagy, and upregulates endogenous antioxidant enzymes (e.g., HO-1, catalase, SOD). Recombinant human MG53 (rhMG53) or MG53 overexpression reduces infarct size, limits cardiomyocyte apoptosis, and improves functional recovery in rodent ischemia–reperfusion models. Additional benefits include suppression of NF-κB–mediated inflammation and modulation of necroptotic pathways via RIPK1 ubiquitination. However, there are conflicting data: chronic MG53 upregulation in some models has been associated with insulin signaling perturbation, and human data remain limited with variable reports on the cardiac MG53 expression and circulating levels. Safety, pharmacokinetics, and optimal delivery strategies for rhMG53 require further characterization. Conclusion: MG53 represents a promising cardioprotective target for MI through multimodal actions on membrane repair, mitochondrial protection, and antioxidant gene regulation. Translation to clinical therapy will require rigorous preclinical safety profiling, clarification of MG53’s systemic metabolic effects, and well-designed early-phase studies to evaluate pharmacology, dosing, and efficacy in humans. Future studies should explicitly address human expression patterns and reconcile metabolic concerns to safely harness MG53-based in-terventions.
- 3 May 2026
- Published by Maad Rayan Publishing Company in Journal of Kerman University of Medical Sciences
- Vol. 33  (1) , 1-9
MG53 as a Potential Therapeutic Target for Myocardial Infarction Injury
Introduction: Myocardial infarction (MI) leads to irreversible cardiomyocyte loss and progressive ventricular remodeling largely driven by oxidative stress, inflammation, and mitochondrial dysfunction. Mitsugumin 53 (MG53/TRIM72) is a muscle-enriched membrane-repair protein that has emerged as a multifunctional regulator of cellular antioxidant responses, mitochondrial integrity, and anti-inflammatory signaling. This review synthesizes current evidence on the MG53’s mechanisms and therapeutic potential in MI. Methods: We performed a narrative review of preclinical and translational literature focusing on MG53 in cardiac injury. Databases searched included PubMed and Google Scholar (through 2025), using keywords "MG53," "TRIM72," "myocardial infarction," "isch-emia-reperfusion," "recombinant MG53," and "cardioprotection." Relevant mechanistic studies, recombinant protein interventions, and reports on the MG53’s systemic effects and safety were prioritized. Results: Preclinical studies demonstrate that MG53 promotes plasma-membrane resealing, preserves mitochondrial membrane potential, reduces mitochondrial ROS production, attenuates mitophagy, and upregulates endogenous antioxidant enzymes (e.g., HO-1, catalase, SOD). Recombinant human MG53 (rhMG53) or MG53 overexpression reduces infarct size, limits cardiomyocyte apoptosis, and improves functional recovery in rodent ischemia–reperfusion models. Additional benefits include suppression of NF-κB–mediated inflammation and modulation of necroptotic pathways via RIPK1 ubiquitination. However, there are conflicting data: chronic MG53 upregulation in some models has been associated with insulin signaling perturbation, and human data remain limited with variable reports on the cardiac MG53 expression and circulating levels. Safety, pharmacokinetics, and optimal delivery strategies for rhMG53 require further characterization. Conclusion: MG53 represents a promising cardioprotective target for MI through multimodal actions on membrane repair, mitochondrial protection, and antioxidant gene regulation. Translation to clinical therapy will require rigorous preclinical safety profiling, clarification of MG53’s systemic metabolic effects, and well-designed early-phase studies to evaluate pharmacology, dosing, and efficacy in humans. Future studies should explicitly address human expression patterns and reconcile metabolic concerns to safely harness MG53-based in-terventions.
- 1 August 2024
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 24  (2) , 105-116
A Comprehensive Review of the Pharmacological Effects of Genus Ferula on Central Nervous System Disorders
Background: Plants of the genus Ferula have long been used to treat neurological diseases such as Alzheimer's disease (AD), pain, depression, and seizures. The main compounds include coumarins, monoterpenes, sulfide compounds, and polyphenol compounds, which can improve the functioning of the nervous system. Objective: This article has been compiled with the aim of collecting evidence and articles related to the Ferula effects on central nervous system disease. Methods: This review article was prepared by searching the terms Ferula and analgesic, anticonvulsant, antidepressant, anti-multiple sclerosis, anti-dementia, and neuroprotective effects.The relevant information was collected through searching electronic databases such as ISI Web of Knowledge, PubMed, and Google Scholar. Results: Genus Ferula has a protective effect on nerve cells by reducing cytokines such as IL-6, IL- 1b, and TNF-α. Therefore, the effects of Ferula plants and their effective ingredients can be used to prevent or improve diseases that destroy the nervous system. The members of this genus play a role in strengthening and improving the antioxidant system, reducing the level of oxidative stress, and inhibiting or reducing inflammatory factors in the nervous system. Conclusion: Although the effects of several species of Ferula on the nervous system have been investigated, most studies have not clearly identified the molecular mechanisms as well as the specific functional regions of the brain. The present study was compiled in order to investigate different aspects of the effects of Ferula plants on the central nervous system.
- 1 August 2024
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 24  (2) , 105-116
A Comprehensive Review of the Pharmacological Effects of Genus Ferula on Central Nervous System Disorders
Background: Plants of the genus Ferula have long been used to treat neurological diseases such as Alzheimer's disease (AD), pain, depression, and seizures. The main compounds include coumarins, monoterpenes, sulfide compounds, and polyphenol compounds, which can improve the functioning of the nervous system. Objective: This article has been compiled with the aim of collecting evidence and articles related to the Ferula effects on central nervous system disease. Methods: This review article was prepared by searching the terms Ferula and analgesic, anticonvulsant, antidepressant, anti-multiple sclerosis, anti-dementia, and neuroprotective effects.The relevant information was collected through searching electronic databases such as ISI Web of Knowledge, PubMed, and Google Scholar. Results: Genus Ferula has a protective effect on nerve cells by reducing cytokines such as IL-6, IL- 1b, and TNF-α. Therefore, the effects of Ferula plants and their effective ingredients can be used to prevent or improve diseases that destroy the nervous system. The members of this genus play a role in strengthening and improving the antioxidant system, reducing the level of oxidative stress, and inhibiting or reducing inflammatory factors in the nervous system. Conclusion: Although the effects of several species of Ferula on the nervous system have been investigated, most studies have not clearly identified the molecular mechanisms as well as the specific functional regions of the brain. The present study was compiled in order to investigate different aspects of the effects of Ferula plants on the central nervous system.
- Open Access
- 1 April 2022
- Published by CMV Verlag in Physiology and Pharmacology
- Vol. 26  (1) , 7-19
Enriched-asafoetida diet attenuates hyperglycemia, oxidative stress and endothelial dysfunction in type 2 diabetic rats
Introduction: It has been documented that oxidative stress and inflammation are the main causes of diabetic-induced disorders. Several studies have been reported the antioxidant and antidiabetic effects of prepared asafoetida extracts, from Ferula assa-foetida L. species in the Apiaceae family. The aim of the present study was to evaluate the ...
- 1 April 2022
- Published by CMV Verlag in Physiology and Pharmacology
- Vol. 26  (1) , 7-19
Open AccessEnriched-asafoetida diet attenuates hyperglycemia, oxidative stress and endothelial dysfunction in type 2 diabetic rats
Introduction: It has been documented that oxidative stress and inflammation are the main causes of diabetic-induced disorders. Several studies have been reported the antioxidant and antidiabetic effects of prepared asafoetida extracts, from Ferula assa-foetida L. species in the Apiaceae family. The aim of the present study was to evaluate the ...
- Open Access
- 1 July 2020
- Vol. 10  (4) , 407-416
Role of the potassium channels in vasorelaxant effect of asafoetida essential oil
Objective: In a previous work, we showed that asafoetida essential oil (AEO), from oleo-gum resin of Ferula asafoetida L. from the Apiaceae family, has a vasodilatory effect. This effect was both endothelium-dependent and endothelium-independent. The present study was designed to determine whether potassium channels and intracellular calcium release contribute to AEO-induced vasodilation. Materials and Methods: Rats' thoracic aorta were isolated and denuded. Following induction of contraction by potassium chloride (60 mM), concentration-response curve was plotted by the cumulative addition of AEO (0.625-80 mu l/l to the medium of rings. The vasodilatory effect of AEO was assessed before and after addition of phenylephrine and potassium channel blockers (including barium chloride (BC), 4-aminopyridine (4A) and glibenclamide (Gl)). Results: AEO relaxed the precontracted rings in a concentration-dependent manner (IC50=23 mu l/l). All potassium channel blockers significantly attenuated the vasodilatory activity of AEO when they were added to rings medium before addition of KCl (p<0.01, 4A and Gl groups and p<0.001, BC group vs. control group) but not after that. In contrast to K channel blockers, adding AEO before or after phenylephrine, the tension was reduced significantly (p<0.05 vs. the control group). Conclusion: The findings of this study indicated that the vasodilatory effect of AEO on denuded-endothelium aortic ring was mediated through activation of potassium channels and reduced intracellular calcium release.
- 1 July 2020
- Vol. 10  (4) , 407-416
Open AccessRole of the potassium channels in vasorelaxant effect of asafoetida essential oil
Objective: In a previous work, we showed that asafoetida essential oil (AEO), from oleo-gum resin of Ferula asafoetida L. from the Apiaceae family, has a vasodilatory effect. This effect was both endothelium-dependent and endothelium-independent. The present study was designed to determine whether potassium channels and intracellular calcium release contribute to AEO-induced vasodilation. Materials and Methods: Rats' thoracic aorta were isolated and denuded. Following induction of contraction by potassium chloride (60 mM), concentration-response curve was plotted by the cumulative addition of AEO (0.625-80 mu l/l to the medium of rings. The vasodilatory effect of AEO was assessed before and after addition of phenylephrine and potassium channel blockers (including barium chloride (BC), 4-aminopyridine (4A) and glibenclamide (Gl)). Results: AEO relaxed the precontracted rings in a concentration-dependent manner (IC50=23 mu l/l). All potassium channel blockers significantly attenuated the vasodilatory activity of AEO when they were added to rings medium before addition of KCl (p<0.01, 4A and Gl groups and p<0.001, BC group vs. control group) but not after that. In contrast to K channel blockers, adding AEO before or after phenylephrine, the tension was reduced significantly (p<0.05 vs. the control group). Conclusion: The findings of this study indicated that the vasodilatory effect of AEO on denuded-endothelium aortic ring was mediated through activation of potassium channels and reduced intracellular calcium release.
- Open Access
- 1 October 2016
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 7  (4) , 224-230
Effect of oleuropein on myocardial dysfunction and oxidative stress induced by ischemic-reperfusion injury in isolated rat heart
- 1 October 2016
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 7  (4) , 224-230
Open AccessEffect of oleuropein on myocardial dysfunction and oxidative stress induced by ischemic-reperfusion injury in isolated rat heart
- Open Access
- 1 January 2016
- Published by Maad Rayan Publishing Company in The International Journal of Occupational and Environmental Medicine
- Vol. 7  (1) , 15-21
The Effect of Atorvastatin on Preventing Noise-Induced Hearing Loss: An Experimental Study
The Effect of Atorvastatin on Preventing Noise-Induced Hearing Loss: An Experimental Study
- 1 January 2016
- Published by Maad Rayan Publishing Company in The International Journal of Occupational and Environmental Medicine
- Vol. 7  (1) , 15-21
Open AccessThe Effect of Atorvastatin on Preventing Noise-Induced Hearing Loss: An Experimental Study
The Effect of Atorvastatin on Preventing Noise-Induced Hearing Loss: An Experimental Study
- Open Access
- 6 June 2015
- Vol. 20  (1) , 41-48
Prophylactic and Therapeutic Effects of Oleuropein on Reperfusion-Induced Arrhythmia in Anesthetized Rat
This study was conducted to reveal that whether i.v. injection of oleuropein, the most potent polyphenolic antioxidant in olive leaf, has any effect on the magnitude of reperfusion arrhythmia in anesthetized rats or not. Eighty male Wistar rats were divided into 8 groups of 10 each: groups 1 and 5 were assigned as the prophylactic and treatment control groups, groups 2 and 6 as the prophylactic and treatment groups with lidocaine (10 mg/kg), groups 3 and 4 as the prophylactic groups with 10 and 50 mg/kg oleuropein (i.v.), and groups 7 and 8 as the treatment groups with 10 and 50 mg/kg oleuropein (i.v.), respectively. Reperfusion injury was induced by 5-min regional ischemia and 15-min reperfusion of left anterior descending coronary artery. Heart rate, blood pressure, and electrocardiogram were monitored throughout the procedure. blood pressure was significantly decreased by infusion of 50 mg/kg oleuropein in groups 4 and 8, but unlike the lidocaine as a standard anti-arrhythmic drug in groups 2 and 5 had not significant effect on heart rate. The onset of arrhythmia in groups received oleuropein (groups 3, 4, 7, and 8) was significantly delayed. The mortality rate due to irreversible ventricular fibrillation was also significantly reduced in groups 3, 4, 7, and 8. The effect of lidocaine in groups 2 and 5 was more potent than that in oleuropein group. These findings indicate that i.v. injection of oleuropein possibly through its antioxidant activity reduces the magnitude of reperfusion-induced arrhythmia.
- 6 June 2015
- Vol. 20  (1) , 41-48
Open AccessProphylactic and Therapeutic Effects of Oleuropein on Reperfusion-Induced Arrhythmia in Anesthetized Rat
This study was conducted to reveal that whether i.v. injection of oleuropein, the most potent polyphenolic antioxidant in olive leaf, has any effect on the magnitude of reperfusion arrhythmia in anesthetized rats or not. Eighty male Wistar rats were divided into 8 groups of 10 each: groups 1 and 5 were assigned as the prophylactic and treatment control groups, groups 2 and 6 as the prophylactic and treatment groups with lidocaine (10 mg/kg), groups 3 and 4 as the prophylactic groups with 10 and 50 mg/kg oleuropein (i.v.), and groups 7 and 8 as the treatment groups with 10 and 50 mg/kg oleuropein (i.v.), respectively. Reperfusion injury was induced by 5-min regional ischemia and 15-min reperfusion of left anterior descending coronary artery. Heart rate, blood pressure, and electrocardiogram were monitored throughout the procedure. blood pressure was significantly decreased by infusion of 50 mg/kg oleuropein in groups 4 and 8, but unlike the lidocaine as a standard anti-arrhythmic drug in groups 2 and 5 had not significant effect on heart rate. The onset of arrhythmia in groups received oleuropein (groups 3, 4, 7, and 8) was significantly delayed. The mortality rate due to irreversible ventricular fibrillation was also significantly reduced in groups 3, 4, 7, and 8. The effect of lidocaine in groups 2 and 5 was more potent than that in oleuropein group. These findings indicate that i.v. injection of oleuropein possibly through its antioxidant activity reduces the magnitude of reperfusion-induced arrhythmia.
- Open Access
- 1 January 2014
- Published by SAGE Publications in Pharmacognosy Magazine
- Vol. 10  (38) , 147-53
Pretreatment with Assafoetida exerts dose-dependent dual effects on rat hearts
Context: Although many studies displayed the favorable effects of Assafoetida, some of them reported that high doses of Assafoetida could lead to harmful effects. Aims: In this study, the effect of pretreatment with Assafoetida investigated on ischemic-reperfusion injury in isolated rat heart model. Materials and Methods: Thirty two male Wistar rats were divided into 4 groups of eight. Group 1 as the control (Con) group and three other groups as the treatment groups that given Assafoetida by gavage at levels of 25, 50 and 100 mg/kg, once a day for four weeks (T25, T50 and T100 groups). Then their hearts were subjected to 30 min global ischemia and 90 min reperfusion under langendorff apparatus. Results: The data shown that hemodynamic parameters including left ventricular developed pressure (LVDP) and maximum and minimum of pressure changes (±dp/dt) were increased in T25 and decreased in T50 and T100 groups during reperfusion in comparison with Con group. There was not any significant difference in the incidence of irreversible ventricular fibrillation between T25 and Con group, while it was increased in T50 and T100 groups significantly. There was not any significant difference in infarct size between all groups. Conclusion: These data indicate that pretreatment of rats with Assafoetida have cardioprotective effects in low doses and cardiotoxic effects in higher doses. Therefore, it needs more investigation in the future.
- 1 January 2014
- Published by SAGE Publications in Pharmacognosy Magazine
- Vol. 10  (38) , 147-53
Open AccessPretreatment with Assafoetida exerts dose-dependent dual effects on rat hearts
Context: Although many studies displayed the favorable effects of Assafoetida, some of them reported that high doses of Assafoetida could lead to harmful effects. Aims: In this study, the effect of pretreatment with Assafoetida investigated on ischemic-reperfusion injury in isolated rat heart model. Materials and Methods: Thirty two male Wistar rats were divided into 4 groups of eight. Group 1 as the control (Con) group and three other groups as the treatment groups that given Assafoetida by gavage at levels of 25, 50 and 100 mg/kg, once a day for four weeks (T25, T50 and T100 groups). Then their hearts were subjected to 30 min global ischemia and 90 min reperfusion under langendorff apparatus. Results: The data shown that hemodynamic parameters including left ventricular developed pressure (LVDP) and maximum and minimum of pressure changes (±dp/dt) were increased in T25 and decreased in T50 and T100 groups during reperfusion in comparison with Con group. There was not any significant difference in the incidence of irreversible ventricular fibrillation between T25 and Con group, while it was increased in T50 and T100 groups significantly. There was not any significant difference in infarct size between all groups. Conclusion: These data indicate that pretreatment of rats with Assafoetida have cardioprotective effects in low doses and cardiotoxic effects in higher doses. Therefore, it needs more investigation in the future.
- Open Access
- 1 January 2012
- Vol. 11  (4) , 1255-63
Prolonged Oral Administration of Oleuropein Might Protect Heart against Aconitine-induced Arrhythmia.
In this study, it was surveyed to know whether an oral single dose of oleuropein could mimic the cardiac preconditioning in rats' hearts or whether its prolonged oral administration could protect the heart against the aconitine-induced arrhythmia in rats. Eighty male Wistar rats were divided into two series (n = 8 in each group). In the first series, all groups (except the control (Con) group) were given a single oral dose of oleuropein (20 mg/Kg) 1, 3, 24 and 48 h before the infusion of aconitine. In the second series, except the Con group, the other four groups were given oral oleuropein (20 mg/Kg/day) for 3, 7, 14 and 28 days, before the infusion of aconitine. Electrocardiogram was recorded to monitor arrhythmia. Data of the first series showed that the initiation time of arrhythmia, the initiation of ventricular tachycardia (VT), the numbers of reversible ventricular fibrillation (VF) and the death time had no significant difference compared with Con group. In the second series, a significant protection was occurred only in the 28 days group that was evident with increased initiation time of arrhythmia, increased initiation time of VT, and increased the number of reversible VF and death time in compared to the Con group. The findings of this study show that the oral administration of a single dose of oleuropein could not mimic the preconditioning effects in rat hearts, but the prolonged administration of oleuropein for about four weeks could protect the heart against aconitine-induced arrhythmia.
- 1 January 2012
- Vol. 11  (4) , 1255-63
Open AccessProlonged Oral Administration of Oleuropein Might Protect Heart against Aconitine-induced Arrhythmia.
In this study, it was surveyed to know whether an oral single dose of oleuropein could mimic the cardiac preconditioning in rats' hearts or whether its prolonged oral administration could protect the heart against the aconitine-induced arrhythmia in rats. Eighty male Wistar rats were divided into two series (n = 8 in each group). In the first series, all groups (except the control (Con) group) were given a single oral dose of oleuropein (20 mg/Kg) 1, 3, 24 and 48 h before the infusion of aconitine. In the second series, except the Con group, the other four groups were given oral oleuropein (20 mg/Kg/day) for 3, 7, 14 and 28 days, before the infusion of aconitine. Electrocardiogram was recorded to monitor arrhythmia. Data of the first series showed that the initiation time of arrhythmia, the initiation of ventricular tachycardia (VT), the numbers of reversible ventricular fibrillation (VF) and the death time had no significant difference compared with Con group. In the second series, a significant protection was occurred only in the 28 days group that was evident with increased initiation time of arrhythmia, increased initiation time of VT, and increased the number of reversible VF and death time in compared to the Con group. The findings of this study show that the oral administration of a single dose of oleuropein could not mimic the preconditioning effects in rat hearts, but the prolonged administration of oleuropein for about four weeks could protect the heart against aconitine-induced arrhythmia.